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Reading Time: 10 minutes 
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INSTRUCTIONS TO CANDIDATES 
Answer all questions in Section A on the MCQ answer sheet proved. 
 
Answer all questions in Section B in the booklet provided. 
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You may begin writing from the commencement of the examination session.  The reading time indicated above is 
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Section A 
Multiple Choice Questions 
Total No of Marks for this Section:  50 
 
 
This section should be answered on the Answer Sheet provided.  Please ensure that your name and 
student number have been written on the Answer sheet and placed in the completed Answer Booklet. 
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Section B 
Short Answer Questions: 11 
Total No of Marks for this Section:  75 
 
This section should be answered in the Answer Book provided. 
 
 










Redraw the structure in your answer paper and label all the possible binding interactions that 
can take place in the binding site between dobutamine molecules and the amino acid residues of 
the beta-adrenergic receptor protein involved. 
(Marks: 3) 
 
(b) What is meant by de novo drug design? 
(Marks: 1) 
 
(c) The logP value of dobutamine is 1.94. Calculate the other properties of dobutamine relating to 
‘Lipinski-Rule of Five’. State whether the molecule is drugable and explain your answer. 
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(a) The graph below represents a plot of %concentration versus pH of diazepam.  




(i) What does the logP value indicate about the nature of the molecule? 
 
(ii) Discuss the nature of the major species at pH 7.4. 
 
(iii) Calulate the logD value fo the molecule at pH 5.5. 
 
 
  -- for acids 
 -- for bases 
(Marks: 4) 
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(c) In reference to the figure below, discuss the significance of Ramachandran plot in homology 
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LogP of benzoic acid is 1.89. Using the data provided in the table below, for substituents of benzoic acid 




(a) Calulcate the logP value for: 
- Nitrobenzoic acid 
- Aminobenzoic acid 
- Chlorobenzoic acid 
(Marks: 3) 
 
(b) Which of the above three (3) compounds will be most hydrophobic? Explain your answer. 
(Marks: 2) 
 
(c) What position of the benzoic acid would you add the amino group to, to make the acid stronger? 
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Explain the role of UDP-glucuronosyltransferases play in bladder carcinogenesis. 
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Laura is 14 and a forward on her school soccer team and leads the league scoring. For the last four 
months she has been really tired, but nothing seemed really wrong until her legs became covered in 
bruises. Just pressing her fingers on her skin was enough to make a bruise!  
 
Beth is 13 and has never been athletic, she prefers reading and theatre. But she has been missing a lot 
of school because of one virus after another, lots of fevers and night sweats and a severe rash.  
 
Both Laura and Beth have been suffering from anaemia, fevers, bleeding and are pale and thin. They 
have been diagnosed with Acute Lymphocytic Leukaemia. Their doctor, Dr. Ryder has decided to keep 
them in the hospital while treating them with a ‘thiopurine’ drug called 6-Mercaptopurine, which is 
known to be highly effective in treating leukaemia. Dr Ryder gives both the girls the same dosage of 
drug before he leaves the hospital for the night. 
 
While making his rounds in the next few days, Dr Ryder sees Laura’s vital signs plummet. Her anaemia 
has worsened; she has a fever and is having difficulty breathing. In contrast, Beth’s anaemia has 
decreased; she is free of fever and is actually showing signs of improved health.  
 
(a) Suggest why the drug might have affected the two girls differently. 
(Marks: 1) 
 
(b) What type of tests could Dr Ryder perform in order to determine how the two girls are reacting 
to the drug? Explain what each test would be determining. 
(Marks: 1) 
 
Dr. Ryder reviews the literature published about thiopurine methyltransferase (TPMT) and finds 
an interesting graph (below). 
 
   
 
(c) What does this graph suggest to you about the genetics of TPMT? Explain your answer and 
include the likely genotypes for each. 
(Marks: 3) 
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Dr Ryder compares the level of Thioguanine nucleotides (TGN) and TPMT enzyme levels in 
patients, and finds the following graph (below).  
  
 
(d) Describe the relationship between TPMT activity, and TGN levels and why they are important. 
(Marks: 2) 
 






(a) What is a transgenic animal? 
(Marks: 1) 
 
(b) When requesting approval to construct a transgenic animal, the work needs to align to one of six 
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A group of 20 recurrence breast cancer patients (taking tamoxifen) were selected for a study, regarding 
tamoxifen treatment. 19 aged matched women who had already completed 5 years of tamoxifen 
treatment with no recurrence, were used as controls. (Table 1). Genomic DNA was collected and 
amplified by PCR to determine if SNPs could influence the efficiency of tamoxifen treatment (Table 2). 
  
Characteristic Case group 
(n = 20) 
Control group  
(n = 19) 











































Table 1: Patient characteristics 
 
SNP Allele Frequencies 
Case group 
(n = 20) 
Control group  
(n = 19) 
CYP2D6*10 





























Table 2: Patient genotypes and frequencies  
 
(a) Using the above data, which of the following SNPs most likely plays a role in tamoxifen 
treatment? 
 (Marks: 2) 
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(b) Using your understanding of drug metabolism, explain why the patients displaying the variant 
genotype had a shorter disease free survival than the matched controls. 






DNA fragments for two genes (Bt resistance and GFP) were generated through PCR with the addition of 
restriction enzymes (HindIII) at the 5’- and 3’-ends. The DNA fragments were inserted into a plasmid and 
transformed into plants so that they were resistant to certain insects (Bt gene) as well as fluoresce (GFP 
gene). 
 
(a) List the reagents that are necessary for a reaction to occur and explain the role of each reagent. 
(Marks: 4) 
 




(c) List three (3) advantages of PCR. 
(Marks: 3) 
 
(d) Would it have been possible for the plant to be transformed with the Bt gene and not the GFP 






Jane is a 47-year-old female who was stabilised on warfarin (a substrate for CYP2C9), with her 
prothrombin time being optimised by substantially increasing the normal dosage of anticoagulant 
required, despite her blood levels being within normal limits. Ten (10) days later Jane stops taking 
rifampicin and she suffers a mild haemorrhage. Explain what might have happened to Jane.  
 
 
(Marks: 4) 
